77 related articles for article (PubMed ID: 20543102)
1. Long peptide vaccination can lead to lethality through CD4+ T cell-mediated cytokine storm.
Kitamura H; Sedlik C; Jacquet A; Zaragoza B; Dusseaux M; Premel V; Sastre-Garau X; Lantz O
J Immunol; 2010 Jul; 185(2):892-901. PubMed ID: 20543102
[TBL] [Abstract][Full Text] [Related]
2. Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2.
Mochimaru H; Nagai N; Hasegawa G; Kudo-Saito C; Yaguchi T; Usui Y; Kurihara T; Koto T; Satofuka S; Shinoda H; Ozawa Y; Tsubota K; Kawakami Y; Ishida S
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4795-801. PubMed ID: 17898306
[TBL] [Abstract][Full Text] [Related]
3. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
4. Antigen-experienced CD4(+) T cells limit naïve T-cell priming in response to therapeutic vaccination in vivo.
Schiering C; Guarnerio J; Basso V; Muzio L; Mondino A
Cancer Res; 2010 Aug; 70(15):6161-70. PubMed ID: 20631073
[TBL] [Abstract][Full Text] [Related]
5. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
7. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
8. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists.
Welters MJ; Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; Offringa R; van der Burg SH
Vaccine; 2007 Feb; 25(8):1379-89. PubMed ID: 17123670
[TBL] [Abstract][Full Text] [Related]
9. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.
Hervas-Stubbs S; Majlessi L; Simsova M; Morova J; Rojas MJ; Nouzé C; Brodin P; Sebo P; Leclerc C
Infect Immun; 2006 Jun; 74(6):3396-407. PubMed ID: 16714570
[TBL] [Abstract][Full Text] [Related]
10. Major histocompatibility complex regulation of T helper functions mapped to a peptide C terminus that controls ligand density.
Murray JS; Ferrandis-Edwards D; Wolfe CJ; Schountz T
Eur J Immunol; 1994 Oct; 24(10):2337-44. PubMed ID: 7925562
[TBL] [Abstract][Full Text] [Related]
11. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.
Abrams SI; Dobrzanski MJ; Wells DT; Stanziale SF; Zaremba S; Masuelli L; Kantor JA; Schlom J; Masuelle L [corrected to Masuelli L]
Eur J Immunol; 1995 Sep; 25(9):2588-97. PubMed ID: 7589131
[TBL] [Abstract][Full Text] [Related]
12. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
13. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
Maecker HT; Umetsu DT; DeKruyff RH; Levy S
J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
[TBL] [Abstract][Full Text] [Related]
15. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
[TBL] [Abstract][Full Text] [Related]
16. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
18. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
[TBL] [Abstract][Full Text] [Related]
19. The differentiated state of intestinal lamina propria CD4+ T cells results in altered cytokine production, activation threshold, and costimulatory requirements.
Hurst SD; Cooper CJ; Sitterding SM; Choi Jh; Jump RL; Levine AD; Barrett TA
J Immunol; 1999 Dec; 163(11):5937-45. PubMed ID: 10570280
[TBL] [Abstract][Full Text] [Related]
20. Suppression of alkali burn-induced corneal neovascularization by dendritic cell vaccination targeting VEGF receptor 2.
Mochimaru H; Usui T; Yaguchi T; Nagahama Y; Hasegawa G; Usui Y; Shimmura S; Tsubota K; Amano S; Kawakami Y; Ishida S
Invest Ophthalmol Vis Sci; 2008 May; 49(5):2172-7. PubMed ID: 18263815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
